78 TESTING Effects studied include decrease of the telogen
hair density, increase of the anagen hair density, increase of the growth coefficient (A/T) ratio at baseline, midpoint and at end of treatment phase. For hair replenishment products, trained evaluators assess the subjects’ hair for attributes of shine, volume, thickness, softness, and general appearance/condition at baseline and after eight to 12 weeks approximately. The Brush Friction Count Method (BFCM) is
employed, and intact and broken hair are each counted. Macro photographs are taken of an area on the head with thinning hair and assessed for hair growth and count at baseline and/or at midpoint and at end of treatment period. Also, self-evaluation by subjects for any perceived improvements of specific criteria can provide useful information about the product. Depending on the clinical end points sought,
hair evaluations can involve assessment of hair density, thickness, moisture, frizz control, static, hair manageability, combing forces, hair shine, hair volume, hair breakage, hair softness, hair suppleness, hair colour, curl effect, curl retention, gloss, hair anti-loss/growth and hair photo protection. Scalp evaluations include dryness/flaking,
hydration, irritation, inflammation, erythema, pruritus, oiliness, fatty acids, cytokine levels, overall scalp analyses with in vivo digital photography/microscopy. Lately, there has been a huge surge of requests
for testing efficacy of hair care products that includes shampoo, conditioner, scalp oils, hair serums and dietary supplements. Substantiation of claims include stimulates hair growth, extends hair life, restores hair vitality, denser hair. It is important to expand knowledge and experience to keep up with the evolving trends as demands for hair and scalp grooming increases.
Testing Presented here is the testing of a hair serum made with natural ingredients. The objective was to test its efficacy, safety and acceptability on improvement in hair loss in a well thought out clinical design. Thirty-five healthy females with mild to
Mean Corneometer Values
80.00 70.00 60.00 50.00 40.00 30.00 20.00 10.00 0.00
0 1 2 4
TABLE 1: RESULTS OF HAIR HEALTH TESTING Ingredients
Evaluation Hair Shine Hair Volume Hair Softness Healthy appearance
Baseline Week 4 Week 8 Week 12 Baseline Week 4 Week 8 Week 12 Baseline Week 4 Week 8 Week 12 Baseline Week 4 Week 8 Week 12
N
31 31
30 30 31 31
30 30 31 31
30 30 31 31
30 30
* Percent change is calculated from the mean changes from baseline TABLE 2: BRUSH FRICTION COUNT Attribute
Group
Brush Friction
Broken/ Damaged (Hair)
Intact (Hair) * Significant changes from baseline
moderate hair thinning who met the inclusion exclusion criteria and agreed to prohibitions and restrictions of the study evaluated effects of a hair serum in a three-month open-label clinical trial. The TA was provided to be used twice daily once in the morning and once at night. On study visit days - baseline, four, eight
Mean TEWL Values
12.0 10.0 8.0 6.0 4.0 2.0 0.0
11.3 8.7 8.5 8.2
and 12 weeks, hair and scalp health was assessed using expert grading for both scalp and hair health attributes, Brush friction method for hair strength and instruments for scalp hydration (Corneometer®), scalp barrier function (Tewameter®)(Courage and Khazaka Germany). Also included were measurement and
analyses with a high-resolution trichoscope using AI imaging Hair Metrix VISIOMED® D200EVO (Canfield Scientific, USA) at baseline and different time points of the study, 48 hours after clipping of the hair.
The parameters analysed with the HairMetrix® included hair count, T:V ratio, average number of follicular unit, average hair width, follicular count/ cm2
0 1 2 4
Figure 1: Scalp health tests. Corneometer (hydration) and Tewameter values (Barrier function) at baseline, four, eight and 12 weeks
PERSONAL CARE MAGAZINE March 2026
dermatoscope. Subject self-perception data was also collected. Our results suggest that the hair serum tested in this study is an effective, safe, well-tolerated, for individuals with hair thinning. No adverse events were reported during the 12-week study period.
Discussion Conventional therapies for alopecia, most notably minoxidil and finasteride, remain the standard
www.personalcaremagazine.com Evaluation Treatment Baseline
Week 12 Baseline Week 12
Treatment Mean
2.32 2.66 3.17 3.75 2.58 2.87 3.18 3.57 2.5
2.73 3.23 3.52 2.81 2.9 3.17
3.53
Mean Difference From Baseline
0.34 0.77 1.17
0.29 0.68 1.07
0.23 0.73 1.02
0.1
0.37 0.73
Within-Treatment Signed-Rank-test
34
0.0010* <0.0001* <0.0001*
0.0002* <0.0001* <0.0001*
0.0039* <0.0001* <0.0001*
0.125
0.0077* <0.0001*
Treatment Mean
6.57
4.90 4.00 2.73
- 1.67 - 1.27 <0.0001* <0.0001* 26 25 86.7% 83.3%
Mean Difference from Baseline
Within-Treatment Signed Rank-test p-value
Number Improved
Percent Improved
and inter follicular distance by high-resolution
Mean Corneometer Value
Mean TEWL Value (g/m2/hr)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
